Feb 29, 2024
The maker of Levemir FlexPens and vials will stop making the man-made insulin this year.
Flexpens will be discontinued on April 1, 2024. Vials of the drug will be discontinued on December 31, 2024. CarelonRx will be notifying roughly 5,000 members who have recently filled Levemir by March 1, 2024, to tell them about the discontinuation and alternative insulins covered by their plan. Levemir will be removed from most of Anthem’s commercial formularies on April 1, 2024, and all existing users will be grandfathered.
No formulary changes will be made to the 2023 and 2024 fully insured CT and NY formularies. Traditional and Complete formularies will have Levemir moved to tier 3. Select, Custom BCI, Mercy, and AlohaCare formularies are not impacted.
Anthem will notify employer groups and include a sample of the member communication in the notification.
